The short answer
An interaction between Echinacea purpurea and bictegravir has not been established in a direct human study. Some echinacea preparations change drug-metabolizing enzyme activity, but the findings do not reliably predict a reduction in Biktarvy effectiveness. Have your HIV pharmacist review the exact herbal product before adding it.
What this answer covers
Adult oral Biktarvy with Echinacea purpurea products. Indirect studies used specified root or oral preparations; other echinacea species, plant parts, extracts and mixed cold remedies are not assumed equivalent.
- Supplement or preparation
- Echinacea purpurea
- Medication ingredient
- bictegravir
What have human studies actually found?
In one small study, Echinacea purpurea root changed the handling of an intravenous enzyme-probe medicine while having a different effect on its oral availability. Another study found lower exposure to an oral probe after echinacea, but no significant change in lopinavir/ritonavir exposure. Neither study tested bictegravir. These mixed observations cannot be converted into a measured percentage reduction in Biktarvy levels.
Why might bictegravir respond differently?
Bictegravir is processed through more than one metabolic pathway. An effect on CYP3A alone does not necessarily predict its overall exposure, particularly when an herb can act differently in the liver and intestine. The Liverpool interaction assessment therefore describes a potential weak interaction with very low evidence. The neutral lopinavir result also involved ritonavir, a strong enzyme inhibitor, so it does not establish safety with Biktarvy.
Does the exact echinacea product matter?
Yes. The evidence concerns Echinacea purpurea, and one study specifically used root extract. Products may contain different species, plant parts, extraction methods or additional cold-remedy ingredients. An interaction assessment for one preparation should not be assigned to every bottle labeled echinacea. The available studies do not establish a safe amount, a harmful threshold or a dosing gap that prevents a bictegravir interaction.
What should I discuss before using it?
Tell your HIV pharmacist which product you plan to use, its ingredients and the intended duration. The uncertainty deserves a product-specific review, particularly if viral suppression or medication adherence is already a concern. Continue Biktarvy as prescribed and do not change its dose to compensate for an herbal product. A missing direct study means the answer is uncertain; it does not prove either treatment failure or absence of an interaction.
Evidence and practical considerations
Absorption & effectiveness
An interaction between Echinacea purpurea and bictegravir has not been established in a direct human study. Some echinacea preparations change drug-metabolizing enzyme activity, but the findings do not reliably predict a reduction in Biktarvy effectiveness. Have your HIV pharmacist review the exact herbal product before adding it.
- Exact scope
- Adult oral Biktarvy with Echinacea purpurea products. Indirect studies used specified root or oral preparations; other echinacea species, plant parts, extracts and mixed cold remedies are not assumed equivalent. with Adult oral bictegravir as Biktarvy 50/200/25 mg fixed combination
- Medication form and route
- Adult oral bictegravir as Biktarvy 50/200/25 mg fixed combination; oral botanical product within stated preparation scope
- Timing or duration
- Indirect human studies assessed eight days of a root extract or 28 days of an oral E. purpurea product. No exact-pair exposure or virologic study was identified in the targeted search.
What remains uncertain
- Enzyme-probe and another antiretroviral regimen’s results are indirect. Hepatic and intestinal effects differ, extract composition varies, and there is no established protective spacing interval or quantified bictegravir effect.
Factors that may matter: Exact botanical species, plant part, extract composition and daily amount; Recent initiation, duration or discontinuation of the botanical; Biktarvy fixed-combination components and concurrent medicines; Adherence and viral suppression.
Read the supporting source summaries
Source 1: current U.S. regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People using the fixed combination Biktarvy for HIV treatment; adult-strength tablets contain bictegravir 50 mg, emtricitabine 200 mg and tenofovir alafenamide 25 mg.
Give Biktarvy at least 2 hours before or 6 hours after aluminum/magnesium antacids. Calcium or iron can be taken together with food; routine simultaneous fasting administration or Biktarvy 2 hours after calcium/iron is not recommended. St. John’s wort coadministration is not recommended because bictegravir and tenofovir alafenamide may decrease.
How this applies: Exact bictegravir active ingredient is bridged from bictegravir sodium by the label’s declared equivalent dose. Cation findings concern bictegravir; St. John’s wort can also affect the tenofovir alafenamide component. No emtricitabine interaction is inferred. Exact article scope: Adult oral Biktarvy with Echinacea purpurea products. Indirect studies used specified root or oral preparations; other echinacea species, plant parts, extracts and mixed cold remedies are not assumed equivalent.
Combination-product labeling, not evidence for bictegravir monotherapy. Named antacid directions are not direct experiments on every nutritional magnesium/aluminum formulation. The label supplies no echinacea trial or measured interaction for every multivitamin. Pregnancy has explicit additional fasting instructions.
Source 2: peer-reviewed human enzyme-probe pharmacokinetic study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 12 healthy adults, including six men.
Intravenous midazolam clearance increased 34% and exposure fell 23%, while oral clearance was not significantly changed and oral availability rose from 23% to 33%. Effects at intestinal and hepatic CYP3A sites differed.
How this applies: Indirect Echinacea purpurea mechanism evidence, with opposing intestinal and hepatic observations retained; not a direct bictegravir result. Exact article scope: Adult oral Biktarvy with Echinacea purpurea products. Indirect studies used specified root or oral preparations; other echinacea species, plant parts, extracts and mixed cold remedies are not assumed equivalent.
Bictegravir was not studied. Root extract, short exposure and probe-specific results cannot establish the direction or size of a bictegravir interaction or apply to all echinacea species and preparations. Original abstract only.
Source 3: peer-reviewed human pharmacokinetic study of another antiretroviral regimen
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 13 healthy adults.
Lopinavir and ritonavir exposure were not significantly changed. After echinacea alone, oral midazolam exposure ratio was 0.73 (90% CI 0.61-0.85), indicating CYP3A induction under those conditions.
How this applies: Indirect and partly neutral Echinacea purpurea evidence. It supports mechanistic uncertainty, not a proven bictegravir reduction or a declaration of safety. Exact article scope: Adult oral Biktarvy with Echinacea purpurea products. Indirect studies used specified root or oral preparations; other echinacea species, plant parts, extracts and mixed cold remedies are not assumed equivalent.
Bictegravir was not studied, and ritonavir’s strong enzyme inhibition makes the neutral boosted-protease-inhibitor result unsuitable for direct extrapolation to Biktarvy. Full-text retrieval failed; original abstract was assessed.
Source 4: expert drug-interaction evidence assessment
hiv-druginteractions.org · Source check Sep 10, 2026
Population: People using Biktarvy; exact combination has not been studied in the cited assessment.
Rates the potential interaction as weak and the evidence very low. Hepatic CYP3A induction with intestinal inhibition could modestly decrease bictegravir; bictegravir also undergoes UGT1A1 metabolism. No effect on emtricitabine or tenofovir alafenamide is expected in this assessment.
How this applies: Exact combination-specific interpretation used alongside original echinacea studies; any expected bictegravir change remains uncertain. Exact article scope: Adult oral Biktarvy with Echinacea purpurea products. Indirect studies used specified root or oral preparations; other echinacea species, plant parts, extracts and mixed cold remedies are not assumed equivalent.
Expert prediction from indirect studies, not an exact-pair pharmacokinetic or virologic trial. Botanical species, part and preparation vary. The assessment does not establish a protective dosing interval.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current exact-drug labeling and guidance checked; original human studies and neutral findings assessed. Current statements adjudicated with formulation, food and directional timing corrections. Article written; clinical sign-off not recorded. | |
| Research summary published |
Article revision: 0fd05def206a425c
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.